...from Health and Safety Watch
HSW June 17, 2011 - Health Canada is reviewing the safety of the diabetes drug piglitazone (Actos) - Studies suggest increased risk of bladder cancer
Health Canada reports that in light of studies suggesting an increased risk of bladder cancer with the diabetes drug pioglitazone, as well as actions taken by other regulatory agencies, it is informing healthcare professionals and Canadians that it is undertaking a review of the drug's status.
Pioglitazone is sold in Canada under the brand name "Actos" in addition to generic forms of the drug. It is used by itself or in combination with other diabetes drugs to control blood sugar levels in diabetic patients, when diet and exercise have failed.
See Product Details tab for specifics on the affected items. (unofficial photo)
?Post-marketing reports of bladder cancer have been reported very rarely with the use of pioglitazone. This information is included in the Canadian Product Monograph. Health Canada has been closely monitoring this potential risk, and has been reviewing all relevant studies on an ongoing basis. Health Canada is taking these studies, including their strengths and limitations, into account as we continue to monitor pioglitazone safety.
Should the on-going review identify new safety information, Health Canada will take appropriate action as necessary. This can include updating Canadians with new recommendations regarding pioglitazone and the potential risk of bladder cancer.
The benefits of pioglitazone are considered to outweigh the risks when used as directed in the Canadian Product Monograph. Patients with questions or concerns about their diabetes treatment should talk to their physician or pharmacist.